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Devices
Sample
Size
Average Paclitaxel Conc.
(ng/cm2)
Standard
deviation p value
Lutonix 21 0.34 0.27 <0.001
Medtronic 18 20.39 17.15
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMperformed to either DCB application or no further treatment. Provisional stenting was
discouraged but allowed in both groups. Follow-up angiograms were done after 9
months. For quantitative coronary angiographic analysis CAAS II was used. Primary
efﬁcacy endpoint was late lumen loss (LLL).
Results: 64 patients were randomized to DCB or POBA treatment. Minimal lumen
diameter (0.58  0.22 mm) and grade of stenosis (76.3  8.7 %) were equal in both
groups. Only 5 stents were used as bail out. Angiographic follow-up was achieved in
75 % of patients. The remaining 25 % had telephone follow-up. No patient was lost to
follow-up, no patient died. There was 1 non ST-elevation myocardial infarction in the
POBA group. Restenosis rate was 25 % in the POBA group vs. 6 % in the DCB group
(p¼0.08). Target lesion revascularization was necessary in 3 patients of the POBA vs.
1 patient of the DCB group. The primary endpoint LLL was 0.15 mm in the DCB vs.
0.48 mm in the POBA group (p¼0.035).
Conclusions: Our results underscore the potential of DCBs as stand alone therapy for
bifurcation lesions. Therefore, in bifurcation lesions that show only class A or B
dissection according to the NHLBI classiﬁcation and recoil not beyond 30 % the use
of DCBs is a sound strategy.
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Background: Paclitaxel-coated balloons (PCB) have been proven to be effective for
the treatment of coronary in-stent restenosis (ISR) after bare-metal stent (BMS) or
drug-eluting stent (DES) implantation. This study aims to evaluate the long-term
safety and efﬁcacy of the second-generation SeQuent Please PCB in coronary ISR in
routine real-world practice.
Methods: Between May 2009 and February 2011, all consecutive patients with ISR
lesions treated with the SeQuent Please PCB at our institution were prospectively
included. Patients were followed up for 36 months by clinical observation. The primary
endpoint was the clinically driven target lesion revascularization (TLR) rate at 36
months. The secondary endpoint was the rate of major adverse cardiac events (MACE:
deﬁned as a composite of cardiac death, myocardial infarction, and TLR) at 36 months.
Results: 63 patients with 73 ISR lesions (39 BMS, 34 DES) were included. Mean age
was 67.411.7 years. 77.8 % were male and 55.6 % were diabetics. The majority of
patients presented with stable angina (61.9 %). The target lesion was mainly located in
the right coronary artery (42.5%) and the left anterior descending coronary artery
(38.4%). The mean reference vessel diameter was 3.00.5 mm and the mean target
lesion length was 19.7  6.6 mm. Procedural success was 100 %. Coronary dissection
occurred in 2 patients (3.2 %), requiring additional stent implantation. Follow-up rate
was 92.1 %. The TLR rate was 4.8 % after 36 months. Cumulative MACE at 36
months was 11.1 %, with 4.8 % cardiac death and 3.2 % myocardial infarction. No
vessel thrombosis was documented. The TLR rate did not differ for PCB angioplasty
for BMS-ISR compared with DES-ISR (2.9 % vs. 7.1%, p¼0.58). Baseline lesion
characteristics and procedural data did not differ except for a longer lesion length for
BMS-ISR compared with DES-ISR (21.76.0 mm vs. 17.36.5 mm, p¼0.004).
Conclusions: Treatment of coronary ISR with the second-generation SeQuent Please
PCB provides good clinical outcomes demonstrated by the low TLR rate and low
MACE rates at long-term follow-up.
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Background: DES in-stent restenosis (ISR) is a more complex issue compared to
BMS-ISR. Paclitaxel coated balloons (PCB) are available as an option for DES-ISR
treatment. We aim to evaluate the vascular response to Lutonix PCB as treatment of a
same drug DES-ISR (Paclitaxel) and cross-over drug DES-ISR (-Limus) in a large
animal coronary ISR model.
Methods: 24 DES (8 EES: XIENCE PRO, 8 ZES: Resolute Integrity and 8 PES:
Taxus Liberte) were implanted in naïve porcine coronary arteries at a 1:1.3 over-
stretch. At 30 days post DES deployment all stents were randomized to either Lutonix
PCB (EES/PCB [T1]; ZES/PCB [T2]; PES/PCB [T3]) or POBA (EES/POBA [T4];
ZES/PCB [T5]; PES/PCB [T6]) treatment and they were followed for additional 30
days. Morphometry and safety parameters were assessed by histopathology by a semi-
quantitative score (0¼ not present-4¼overwhelmingly present).
Results: DCB treatment groups display a similar larger lumen area (T1¼5.83.2mm;
T2¼6.32.6mm; T3¼6.11.3) compared to POBA treatment (T4¼5.43.3mm;
T5¼6.12.8mm; T6¼5.92.4mm). Neotintimal area was reduced in the DCB treat-
ment group (T1¼2.90.8; T2¼2.61.3; T3¼3.22.2) compared to POBA groups
(T4¼3.92.1; T5¼4.12; T6¼3.93.5). In histology, similar degree of inﬂammation
was observed among PCB treatment groups (T1¼1.91.5; T2¼1.31.1; T3¼1.91.7)
compared to a slight higher inﬂammatory scores in the POBA treatment groups
(T4¼21; T5¼1.81.2; T6¼2.21). Fibrin deposition was low in all groups
(T1¼0.90.4; T2¼0.60.3; T4¼0.70.9; T5¼0.40.5), however when PES was used
the ﬁbrin score was slightly higher (T3¼1.30.9; T6¼10.5). Complete endothelial
coverage was observed in all treated groups (T1¼3.50.4; T2¼3.80.5; T3¼3.330.8;JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/DrT4¼3.750.3; T5¼40; T6¼3.90.2). The neointima hypocellularity was assessed
showing a similar low score (T1¼10.86; T2¼0.50.8; T3¼1.51; T4¼0.61.2;
T5¼00; T6¼10.3). All treatment groups showed an extremely low thrombosis
score (T1¼0.10.2; T2¼00, T3¼0.20.3; T4¼0.10.2; T5¼00; T6¼00).
Conclusions: Lutonix PCB, in a “cross-over” or “same drug” treatment, seem to be a
safe strategy for DES-ISR without signiﬁcantly increasing inﬂammation or ﬁbrin
deposition in a large animal preclinical model.
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Background: Drug coated balloons (DCBs) employ different coating technologies to
deliver the antirestenotic drug without permanent polymer carrier. The ideal formu-
lation should maximize the neointimal inhibition with the least drug possible, while
ensuring adequate healing and containing the particulate release from the coating. We
evaluated the efﬁcacy of a novel drug coated balloon technology with two clinically
proven DCBs and an uncoated balloon control group in a familial hypercholesterol-
emic swine (FHS) model.
Methods: Twenty four peripheral arteries of 6 FHS were injured at day 0 with an
uncoated balloon, followed by implantation of self-expanding stents in the injured
segments. At day 14, the in-stent restenosis sites were treated with two clinically
proven DCB (In.Pact Paciﬁc Medtronic , 3 ug/mm2 n¼6), and (Lutonix BARD, 2
ug/mm2 n¼6), a novel DCB (Ranger Boston Scientiﬁc, 2 ug/mm2 n¼6), and an
uncoated balloon control (Sterling, Boston Scientiﬁc, n¼6). At day 0, 14 and 42
quantitative vascular analysis and histology at terminatio.
Results: The difference (D) in angiographic percentage diameter stenosis between day
14 and day 42 showed signiﬁcant inhibition of neointimal proliferation with smaller
deltas from baseline in the DCB groups when compared to control (Control: D60%,
Ranger: D10%, InPact: D5%, Lutonix: D10%). The histological data also showed less
neointima and percentage area of stenosis in all DCB groups. Fibrin, a characteristic
hallmark of paclitaxel in arterial tissue, was equivalent in all DCBs and twice as high
as in control. Ranger DCB showed a slightly higher endothelialization score than
In.Pact (Control: 30, Ranger: 2.570.34, In.Pact: 1.850.55, Lutonix: 2.520.35,
p¼< 0.05), and In.Pact had the lowest score of neointima maturity (Control:
2.90.11, Ranger: 1.870.66, In.Pact: 1.480.74, Lutonix: 1.880.49, p¼< 0.05).
Conclusions: All DCBs showed signiﬁcant inhibition of neointimal formation when
compared to the uncoated balloon control. The In.Pact DCB provided strongest
neointimal inhibition but less complete healing. The Ranger DCB provided satisfac-
tory neointimal inhibition and a slightly better healing when compared to In.Pact.
TCT-289
Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use
of Drug Coated Balloon Catheters
Charisse Ward1, Carlos I. Mena1
1Yale University, New Haven, CT
Background: Coating robustness and durability are important characteristics of the
DCB design. Drug that is not ﬁrmly adhering on the balloon surface falls off and could
potentially lead to paclitaxel contamination of work surfaces in the catheterization lab
and expose lab personnel to a toxic chemotherapeutic agent.
Methods: This study sought to determine the coating durability of the Lutonix drug
coated balloon compared to the Medtronic drug coated balloon and to evaluate the
amount of paclitaxel that does not adhere to the balloon and is transferred to work
surfaces during simulated clinical procedural handling. A swab method in the Che-
moGLO kit was used for quantifying trace amount of drug on surface. Both the
Medtronic devices and the Lutonix devices were evaluated in a simulated clinical use
study by three independent physicians at three hospitals. After each physician per-
formed the simulated clinical use test, the surfaces where paclitaxel could have fallen
were swabbed and analyzed for paclitaxel by HPLC (LLQ is 0.01ng/cm2.) The person
performed the swabbing was blinded to the testing devices.
Results: The paclitaxel analysis results from this study and statistical analysis are
summarized on table 1.The ANOVA analysis indicates that paclitaxel surface con-
centrations of the Lutonix devices and the Medtronic devices are statistically different.Conclusions: This study revealed 15 out of 18 Medtronic devices were over the
decontamination level, none of the 21 Lutonix devices was over the decontamination
level. Precautions to avoid working place drug contamination may be required for
handling the Medtronic drug coated balloon catheters. Drug decontamination is rec-
ommended after each time use of the Medtronic DCB catheters to ensure the drug
surface concentration is below 1ng/cm2.ug-Eluting Balloons and Local Drug Delivery B83
